Expert Opinion on Biological Therapy

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	114
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	60
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	54
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	52
Biosimilars and access to biologic therapy in immune-mediated diseases	48
Antibody drug conjugates for glioblastoma: current progress towards clinical use	48
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	40
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	40
The endosomal-lysosomal system in ADC design and cancer therapy	38
Aflibercept biosimilars – so near, yet so far	36
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	33
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	31
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	31
Correction	28
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	28
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	25
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	24
Long-acting delivery and therapies for neovascular age-related macular degeneration	23
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	23
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	22
Signaling new therapeutic opportunities: cytokines in prostate cancer	21
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	20
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	18
Correction	18
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	18

What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	17
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	17
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	17
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	17
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	17
Moving toward personalized approaches in the management of lupus nephritis	17
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u	17
Unmet needs in cervical cancer – can biological therapies plug the gap?	17
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	16
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	16
Strategies for extending the half-life of biotherapeutics: successes and complications	16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	15
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	15
The nail in psoriatic arthritis: new insights into prognosis and treatment	15
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	14
Dynamics of biological markets with multiple biosimilar competitors in the United States	14
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	14
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	14
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	14
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	14
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	14
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	14
Management of proctitis in ulcerative colitis and the place of biological therapies	14
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	14
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	13
Recent advances in delivering RNA-based therapeutics to mitochondria	13
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	13
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?	13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	13
Biological agents targeting interleukin-13 for atopic dermatitis	13
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	12
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	12
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	12
Emerging peptide-based technology for biofilm control	12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	12
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	12
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	12
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	11
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	11
Belimumab patient profile in Spain: evolution during the last decade and future directions	11
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	11
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	11
Non-traditional approaches for control of antibiotic resistance	11

An evaluation of pozelimab for the treatment of CHAPLE disease	11
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	10
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	10
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	10
Biosimilars in osteoporosis treatment: focus on denosumab	10
Clinical management and innovation in fracture non-union	10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	10
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	10
Antibody therapeutics for epithelial ovarian cancer	10
Prostate cancer immunotherapy	10
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
Correction	10
Epcoritamab in B-cell malignancies: current status and prospects	10
Treating psoriasis in the elderly: biologics and small molecules	10
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	10
Tremelimumab for the treatment of hepatocellular carcinoma	10
Sargramostim in acute radiation syndrome	9
X-linked myotubular myopathy: an untreated treatable disease	9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	9
Ravulizumab for the treatment of myasthenia gravis	9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	9
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	9
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	9
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	9
Biologics in rectal cancer	9
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	9
Rilonacept for the treatment of recurrent pericarditis	9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	9
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	8
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	8
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	8
CAR T cells for solid tumors – developments to watch in 2023	8
Hemophilia A gene therapy: current and next-generation approaches	8
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	8
The future of interleukin gene therapy in head and neck cancers	8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	8
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	8
The future of cellular therapy for the treatment of renal cell carcinoma	7
The future of aptamers in cancer diagnosis, prognosis and treatment	7
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	7
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast	7
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	7
The future of cancer vaccines against colorectal cancer	7
Rotavirus vaccines: progress and new developments	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
Non-TNF biologics and their biosimilars in rheumatoid arthritis	7
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	7
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	7
Belantamab mafodotin in multiple myeloma	7
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	7
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	7
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	6
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	6
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	6
Gene therapy for choroideremia: progress, potential and pitfalls	6
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	6
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	6
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	6
Therapeutic monoclonal antibodies for COVID-19 management: an update	6
Correction	6
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	6
Immune checkpoint inhibitors for the treatment of melanoma	6
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma	6
Biological therapies in patients with liver disease: are they really lifesavers?	6
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	6

Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	6
Could siRNA therapeutics change the way we treat dyslipidemia?	6
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	6
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting	6
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	6
Current and preclinical treatment options for Merkel cell carcinoma	6
Perceptions of airway gene therapy for cystic fibrosis	6
Hypoxic storage of red blood cells to improve transfusion outcomes in hematological malignancies	6
The evolving therapeutic landscape of diabetic retinopathy	5
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer	5
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	5
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	5
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	5
Bintrafusp alfa and its unsuccessful development journey towards cervical cancer treatment	5
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	5
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	5
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	5
Recent developments in CD19-targeted therapies for follicular lymphoma	5
How treatment choices influence the onset and outcomes of uveitis ın juvenile idiopathic arthritis: a retrospective cohort study	5
Biologics for dengue prevention: up-to-date	5
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	5
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	5
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	5
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	5
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	5
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	5
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	5
Oncolytic virus therapy for malignant gliomas: entering the new era	5
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects	5
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	5
Pathogenesis-oriented therapy of psoriasis using biologics	5
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	5
Elotuzumab in multiple myeloma	5
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	5
Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia	4
Chasing optimal first-in-human (FIH) starting dose for biotherapeutics in oncology	4
Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM ): a multidisciplinary perspective	4
Targeting cervical cancer with anti-PD-1 antibodies: what is new?	4
Medical students’ knowledge and awareness levels about biologics and biosimilars: the earlier the better?	4
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics	4
Sarilumab in the treatment of rheumatoid arthritis: future perspectives	4
Optimizing the use of vilobelimab for the treatment of COVID-19	4
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence	4
Monoclonal antibodies as adjuvant therapies for resected melanoma	4
The cell replacement therapeutic potential of human pluripotent stem cells	4
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment	4
ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?	4
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch	4
Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review	4
Perispinal etanercept stroke trial design: PESTO and beyond	4
Addressing practical challenges with bispecific antibody therapy in multiple myeloma	4
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?	4
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance	4
Evaluation of canine bone marrow-derived mesenchymal stem cells for experimental full-thickness cutaneous wounds in a diabetic rat model	4
Correction	4
Clinical advances in biological therapy for generalized pustular psoriasis: a review	4
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development	4
Short and long-term economic implications of biosimilars	4
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement	4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2	4
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	4
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors	4
Injectable and adhesive hydrogels for dealing with wounds	3
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease	3
Developing combination therapies with biologics in triple-negative breast cancer	3
Adjuvant immunotherapy for locally advanced renal cell carcinoma	3
What role can LAG-3-blocking antibodies play in melanoma therapy?	3
Biological therapies for myasthenia gravis	3
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	3
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies	3
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participant	3
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	3
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	3
An evaluation of mirikizumab for the treatment of ulcerative colitis	3
Management of metastatic melanoma with combinations including PD-1 inhibitors	3
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	3
Biologics for psoriasis: is there any unmet need left?	3
Biological therapy in elderly patients with acute myeloid leukemia	3
A plain language summary of the pooled safety results of adalimumab-adbm from the VOLTAIRE clinical trials in people with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	3
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	3
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities	3
Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan	3
Mosunetuzumab for the treatment of follicular lymphoma	3
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	3
Switching CGRP(r) MoAbs in migraine: what evidence?	3
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy	3
Antibody-drug conjugates in oncology: insights into Current challenges	3
What is ‘ chronic ’ pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment	3
Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies	3
Recent advances in stem cell therapy for erectile dysfunction: a narrative review	3
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healt	3
Advances in biological and targeted therapies for systemic sclerosis	3
Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States	3
Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments’ evidence: a systematic review an	3
Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy	3